Leuphasyl vs AOD-9604 & CJC-1295 & Ipamorelin (Stack)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Leuphasyl
Leuphasyl (Pentapeptide-18) is a cosmetic peptide that reduces muscle tension through a mechanism similar to enkephalins. Often combined with Syn-Ake for enhanced anti-wrinkle effects.
Full details →AOD-9604 & CJC-1295 & Ipamorelin (Stack)
A targeted fat loss stack combining AOD-9604 (the fat-burning fragment of HGH) with CJC-1295 and Ipamorelin for comprehensive body recomposition. This blend addresses fat loss directly while supporting lean mass through GH optimization.
Full details →Side-by-Side Comparison
| Aspect | Leuphasyl | AOD-9604 & CJC-1295 & Ipamorelin (Stack) |
|---|---|---|
| Mechanism | Mimics enkephalin and binds to enkephalin receptors on muscle cells, reducing acetylcholine release and thereby decreasing muscle contraction intensity. | AOD-9604 stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or blood glucose. CJC-1295 and Ipamorelin provide sustained and pulsatile GH release to support metabolism and lean tissue. The combination targets fat loss through multiple mechanisms while preserving muscle. |
| Typical Dosage | Topical: 3-8% concentration in serums. Often used in combination products with other muscle-relaxing peptides. | Typical protocol: AOD-9604 200-400mcg, CJC-1295 100-200mcg, Ipamorelin 100-200mcg daily. Usually administered in the morning fasted or before exercise. |
| Administration | Topical application to expression lines. Best results with consistent twice-daily use over 8+ weeks. | Subcutaneous injection. Best administered fasted to maximize fat-burning effects. Can be taken as a pre-mixed blend or separate injections. Cycles typically run 8-16 weeks. |
| Side Effects | Very well-tolerated topically. No significant adverse effects reported at cosmetic concentrations. | Mild injection site reactions, headache, nausea. Generally well-tolerated as AOD-9604 lacks many HGH side effects. |
| Best For |